Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.68 USD | +0.74% | -1.70% | +12.03% |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
04-23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.03% | 1.39B | |
+4.93% | 109B | |
+10.86% | 105B | |
-0.38% | 22.25B | |
-11.69% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.57% | 16.85B | |
+4.01% | 13.76B | |
+35.60% | 12.46B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating